Entered into an Agreement to be acquired by QOL Medical Net product sales for the third quarter of 2025 reached $4.3 million; up 61% year-over-year Gimoti patent life for Gimoti extended through November 2038 SOLANA BEACH, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI® (metoclopramide) nasal spray, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “The proposed transaction with QOL Medical reflects this progress and the strategic value we’ve built around GIMOTI and across the broader GI community,” commented Matt D’Onofrio, Chief Executive Officer of Evoke Pharma. “We are proud of the consistent execution that led to...

Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on 10th December, 2025 Fondazion Melanoma Onus will sponsor a new clinical trial (NEO-CYT) at up to 12 cancer centres in Italy to evaluate if MDNA11 in combination with leading check-point inhibitors, prior to surgery (neoadjuvant), can improve outcomes in patients with earlier stage high-risk melanoma MDNA113, Medicenna’s first-in-class tumor-anchored and masked anti-PD-1 x IL-2 bispecific program, is being evaluated in non-human primate studies, with plans for a first-in-human clinical trial to commence in 2026 Six new patents have been issued or allowed across multiple jurisdictions (US, Japan, Canada and Australia) protecting several superkine assets including its wholly-owned anti-PD1...

First patient dosed in Phase 1 clinical trial evaluating AXN-2510/IMM2510 (“’2510”) monotherapy in adult patients with advanced solid tumors DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its third quarter 2025 financial results and provided a corporate update. Recent Highlights:In September, ImmuneOnco, Instil’s collaborator, presented updated data from additional patients with relapsed/refractory squamous non-small cell lung cancer treated with ‘2510 as monotherapy in a poster presentation at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. In October, Axion Bio, Instil’s subsidiary, dosed the first patient in its Phase...

Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential to Convert ‘Cold’ to ‘Hot’ Tumors, Supporting a Frontline Therapy Across the Bladder Cancer Spectrum; Phase 1b/2 Trial is on Track for Data Mid-2026 BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2025, and provided recent business highlights. “In the third quarter, we remained focused on clinical execution in both our global Phase 3 CoMpass trial in early choroidal melanoma and our Phase 1b/2 trial in NMIBC,”...

–   Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes –   Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia –   New data on govorestat for the treatment of PMM2-CDG published in JIMD and presented at the 2025 ASHG Annual Meeting –   Announces Board of Directors Leadership Transition NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today reported financial results for the third quarter ended September 30, 2025. “Our ongoing efforts in operational execution and regulatory progress have yielded important developments in the third quarter and beginning...

– Revenue of $69 million from continuing operations and $14 million from discontinued operations –– Successfully closed $588 million convertible notes offering –– Announced plans to convert Washington site to support GB300s with advanced liquid cooling – TORONTO, Ontario and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Bitfarms Ltd. (Nasdaq/TSX: BITF), a North American energy and digital infrastructure company, today reported its financial results for the third quarter ended September 30, 2025. All financial references are in U.S. dollars. “We continue to execute on our strategy to pivot from an international Bitcoin miner to a North American energy and digital infrastructure company,” stated CEO Ben Gagnon. “We recently announced our successful $588 million convertible note offering, alongside...

Third Quarter Revenue Increased 2.5% Period over Period with 42.3% EBITDA Growth Revenue for the First Nine Months Increased 5.6% Year Over Year Signs Existing Health System to 10 Year Extension and an Upgrade to their Gamma Knife System Conference Call Scheduled for 1:00 PM ET Today SAN FRANCISCO, Nov. 13, 2025 (GLOBE NEWSWIRE) — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its equipment leasing and direct patient care services segments, today announced financial results for the third quarter ended September 30, 2025. Key Financial HighlightsQ3 2025 Revenue increased 2.5% period over period Q3 2025 Direct patient services revenue increased 9.4% period over period Q3...

Disciplined pullback aims to preserve high-quality member base, retention and engagement model, and platform efficiency. CHICAGO, Nov. 13, 2025 (GLOBE NEWSWIRE) — GoHealth, Inc. (NASDAQ: GOCO) (“GoHealth” or the “Company”), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three and nine months ended September 30, 2025. The Company navigated a materially different Medicare Advantage environment by intentionally reducing Medicare Advantage volume, conserving liquidity, and preserving the core capabilities required to scale when market conditions stabilize. Based on our analysis, health plans continue to emphasize margin integrity, renewal stability, and long-term member value over raw enrollment growth. GoHealth anticipated this shift and aligned its operating...

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP) Initiated Phase 1b Study of CLR 125 for TNBC Received Rare Pediatric Drug Designation for Iopofosine I 131 in Inoperable Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the quarter ended September 30, 2025, and provided a corporate update. “Our productive engagement with...

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic BDC, Inc. (“LIEN” or the “Company”) (NASDAQ: LIEN), a specialty finance company that has elected to be regulated as a business development company, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights and Subsequent ActivityTotal gross investment income of $15.1 million. Interest income accounted for $13.8 million, of which $1.9 million was related to one-time pre-payment premiums from early payoffs Net investment income of $9.5 million, or $0.42 per weighted average share outstanding Total investment portfolio of $311.4 million at fair value Net asset value (“NAV”) per share was $13.27 on September 30, 2025 Board of Directors declared a dividend of $0.34 per share for the quarter ending December 31, 2025...